SLC5A2 and diabetes mellitus: According to the 2022 Associations of Medical Diabetologists (AMD) Annals data in Italy, among subjects with DM and high levels of albuminuria, 47.2% were not treated either with SGLT-2 inhibitors or GLP1-R agonists, whereas among subjects with GFR below 60 ml/min, 73.4% of them were not prescribed with SGLT-2 inhibitors [12].